These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 21095464)

  • 1. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COMT inhibition in the treatment of Parkinson's disease.
    Ruottinen HM; Rinne UK
    J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical issues with COMT inhibitors in Parkinson's disease.
    Waters C
    Neurology; 2000; 55(11 Suppl 4):S57-9; discussion S60-4. PubMed ID: 11147511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Issues important for rational COMT inhibition.
    Dingemanse J
    Neurology; 2000; 55(11 Suppl 4):S24-7; discussion S28-32. PubMed ID: 11147507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
    Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
    Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical advantages of COMT inhibition with entacapone - a review.
    Gordin A; Kaakkola S; Teräväinen H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease.
    Schapira AH; Obeso JA; Olanow CW
    Neurology; 2000; 55(11 Suppl 4):S65-8; discussion S69-71. PubMed ID: 11147512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
    Arnold G; Kupsch A
    Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.
    Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group.
    Hauser RA; Molho E; Shale H; Pedder S; Dorflinger EE
    Mov Disord; 1998 Jul; 13(4):643-7. PubMed ID: 9686768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of COMT inhibitors.
    Brooks DJ
    Neurology; 2004 Jan; 62(1 Suppl 1):S39-46. PubMed ID: 14718679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicology and safety of COMT inhibitors.
    Haasio K
    Int Rev Neurobiol; 2010; 95():163-89. PubMed ID: 21095462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.
    Corvol JC; Bonnet C; Charbonnier-Beaupel F; Bonnet AM; Fiévet MH; Bellanger A; Roze E; Meliksetyan G; Ben Djebara M; Hartmann A; Lacomblez L; Vrignaud C; Zahr N; Agid Y; Costentin J; Hulot JS; Vidailhet M
    Ann Neurol; 2011 Jan; 69(1):111-8. PubMed ID: 21280081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
    Haasio K; Sopanen L; Vaalavirta L; Lindén IB; Heinonen EH
    J Neural Transm (Vienna); 2001; 108(1):79-91. PubMed ID: 11261749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New options for treatment of Parkinson's disease.
    LeWitt PA
    Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.